XML 57 R34.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Summary of Significant Accounting Policies (Details)
$ / shares in Units, $ in Thousands
3 Months Ended
May 10, 2024
USD ($)
$ / shares
shares
Jun. 30, 2024
USD ($)
Mar. 31, 2024
USD ($)
segment
$ / shares
Mar. 31, 2023
USD ($)
Dec. 31, 2023
USD ($)
$ / shares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Foreign currency transaction gain (loss)     $ (5,100) $ 16,300  
Number of business segments | segment     1    
Cash and cash equivalents     $ 480,586   $ 568,505
Net income (loss), basic     (147,600)    
Net cash provided by (used in) operating activities     $ (83,555) (325,593)  
Common stock, par value per share (in usd per share) | $ / shares     $ 0.01   $ 0.01
Restructuring and related cost, annual impact percent     85.00%    
Severance and employee benefit costs     $ 4,401    
Impairment of assets     $ 1,669 $ 0  
Sanofi Pasteur Inc. APA | Subsequent Events | Private Placement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Proceeds from equity method investment $ 68,800        
Sale of stock, number of shares issued in transaction (in shares) | shares 6,880,481        
Common stock, par value per share (in usd per share) | $ / shares $ 0.01        
Share, price per share (in usd per share) | $ / shares $ 10.00        
Forecast | Sanofi Pasteur Inc. APA          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Proceeds from collaboration and license agreement   $ 568,800      
Collaboration agreement upfront payment amount   500,000      
Forecast | Sanofi Pasteur Inc. APA | Licensed COVID-19 Products and Royalty Payments          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Development, tech transfer, launch, and sales milestone payments   700,000      
Forecast | Sanofi Pasteur Inc. APA | First Four Adjuvant Products          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Development, tech transfer, launch, and sales milestone payments   200,000      
Forecast | Sanofi Pasteur Inc. APA | Adjuvant Products Thereafter          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Development, tech transfer, launch, and sales milestone payments   $ 210,000